MRE Scan for Brain Tumor Assessment
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a special type of MRI called magnetic resonance elastography (MRE) to study brain tissue in people with gliomas, a type of brain tumor. The goal is to determine if MRE can distinguish between tissue damaged by radiation treatment and tumors that have returned after initial treatment. This capability could help doctors make better decisions in diagnosing and treating these tumors. The trial seeks participants who have had a glioma treated with both chemotherapy and radiation and who have a brain lesion over 2 cm in size. As an unphased trial, this study offers a unique opportunity to contribute to research that could improve diagnostic methods for future patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that magnetic resonance elastography is safe for assessing brain tumors?
Research has shown that magnetic resonance elastography (MRE) is safe. As a non-invasive imaging method, it doesn't require surgery or entering the body. Studies have found that MRE measures the stiffness of brain tissues without causing harm. Clinicians have used this technique in various settings to examine different types of tissues. Because MRE is non-invasive and has been used in numerous studies, it is considered well-tolerated, with no major safety concerns reported.12345
Why are researchers excited about this trial?
Researchers are excited about the use of Magnetic Resonance Elastography (MRE) for brain tumor assessment because it offers a new way to evaluate tumor properties that traditional MRI cannot. Unlike standard MRI, which provides structural images of the brain, MRE measures the stiffness of brain tissues, potentially offering more detailed insights into tumor characteristics. This could help doctors better understand tumor aggressiveness and response to treatment, leading to more personalized and effective care strategies.
What evidence suggests that magnetic resonance elastography is effective for assessing brain tumors?
Research has shown that magnetic resonance elastography (MRE), which participants in this trial will undergo, can help differentiate between types of brain tissue. MRE assesses tissue stiffness, aiding doctors in determining whether tissue is damaged from radiation treatment or if a brain tumor has returned. Studies have found that MRE provides more detailed information about brain tumors than regular MRI. This additional detail may help doctors make more accurate diagnoses and treatment plans. By understanding tissue stiffness, MRE could enhance the monitoring and treatment of brain tumor conditions.12678
Who Is on the Research Team?
Melissa Chen
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with a history of gliomas treated with chemo and radiation, who have a lesion larger than 2 cm. Participants must understand and consent to the study. It excludes pregnant individuals, those allergic to gadolinium-based contrast agents, people with severe kidney issues or GFR <30mL/min/1.73m^2, and anyone with non-MR safe implants or conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic
Participants undergo MRE and standard of care MRI to assess tissue stiffness
Follow-up
Participants undergo standard of care MRI to check the status of the disease
What Are the Treatments Tested in This Trial?
Interventions
- Magnetic Resonance Elastography
- Magnetic Resonance Imaging
Magnetic Resonance Elastography is already approved in United States, European Union for the following indications:
- Diagnostic imaging for gliomas
- Assessment of tissue stiffness in radiation necrosis and recurrent glioma
- Diagnostic imaging for gliomas
- Assessment of tissue stiffness in radiation necrosis and recurrent glioma
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator